Skip to main content

Von Willebrand Disease

Extension Study of Biostate in Subjects With Von Willebrand Disease
NCT01224808 | PHASE 3 | INTERVENTIONAL

The aim of the Von Willebrand Disease (VWD) therapy is to treat and prevent bleeding episodes due to abnormal platelet adhesion and abnormal blood coagulation as a result of low or abnormal Von Willebrand Factor (VWF) and/or Factor VIII (FVIII) levels. The long-term efficacy and safety of a VWF/FVIII concentrate, Biostate, will be investigated in children, adolescents, and adults with VWD in whom treatment with a VWF product is required for prophylactic therapy, haemostatic control during surgery, or control of a non-surgical, spontaneous, or traumatic bleeding event.

Trial Information
6 Sites
20 Participants
Recruiting
12 Years to 65 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Study Site
Sofia,Bulgaria
Study Site
Bremen,Germany
Study Site
Warsaw,Poland
Study Site
Wroclaw,Poland
Study Site
Barnaul,Russian Federation
Study Site
Lviv,Ukraine

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov